Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression

Fig. 1

Serum levels of IGF-1 in relation to acromegaly control and breast cancer evolution. The dotted line represents the upper normal limit for IGF-I, 1. May 2007: Diagnosis of acromegaly (start of octreotide LAR treatment), 2. June 2007: Surgery for breast cancer, 3. February 2008: Trans-sphenoidal adenomectomy, 4. June 2009: Octreotide LAR withdrawal, start pegvisomant, 5. December 2010- January 2011: Diagnosis of lung metastasis of breast cancer, 6. February 2011: Start anastrazol and spontaneous pegvisomant withdrawal, 7. June 2011: Anastrazol withdrawal, start tamoxifen, 8. July 2011: Re-start pegvisomant, 9. September 2011: Reduction in diameter of pulmonary lesions

Back to article page